Trial · NCT02145468
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
NCT02145468, Phase 3, Completed, GlaxoSmithKline; results first posted 2017-06-02
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60). Trials, record NCT02145468. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02145468
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)
- NCT number
- NCT02145468
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 3,503 participants, actual
- Lead sponsor
- GlaxoSmithKline
- Conditions
- Acute Coronary Syndrome
- Interventions
- Losmapimod 7.5 mg twice daily, Placebo twice daily, Standard therapy
- First posted
- 2014-05-23
- Last updated
- 2017-06-02
- Results first posted
- 2017-06-02
Source ClinicalTrials.gov
Registered outcomes26
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Up to 12 weeks | The primary efficacy endpoint is the composite measure of adjudicated MACE that includes the time to first occurrence of CV death (death due to a cardiovascular cause), MI or SRI-UR (Severe Recurrent Ischemia requiring Urgent coronary artery Revascularization). Death for which the Clinical Events Committee (CEC) or investigator were unable to establish cause were analyzed as CV deaths. |
| Secondary | Number of Participants With First Occurrence of MACE Through Week 24 | Up to Week 24 | Number of participants with first occurrence of MACE through Week 24 including CV death, MI or SRI-UR are presented. Death for which the CEC or investigator were unable to establish cause were analyzed as CV deaths. |
| Secondary | Number of Participants With First Occurrence of the Composite of CV Death or MI up to Week 12 and Week 24 | Week 12 and Week 24 | Week 12 results are considered the principal secondary endpoint. Number of participants with first occurrence of the composite of CV death or MI up to Week 12 and Week 24 are summarized. |
| Secondary | Number of Participants With First Occurrence of the Composite of CV Death, MI or Hospitalization for Heart Failure (HF) up to Week 12 and Week 24. | Week 12 and Week 24 | Number of participants with first occurrence of the composite of CV death, MI or hospitalization for HF up to Week 12 and Week 24 are presented. |
| Secondary | Number of Participants With First Occurrence of the Expanded Composite of Arterial CV Events Defined as CV Death, MI, SRI-UR or Stroke Through to Week 12 and Week 24 | Week 12, Week 24 | Number of participants with first occurrence of the expanded composite of arterial CV events defined as CV death, MI, SRI-UR or stroke through to Week 12 and Week 24 are presented. |
| Secondary | Number of Participants With First Occurrence of the Composite of Coronary Events Defined as CHD Death, MI, SRI-UR or Any Unplanned Coronary Artery Revascularization Through to Week 12 and Week 24 | Week 12, Week 24 | Number of participants with first occurrence of the composite of coronary events defined as coronary heart disease (CHD) death, MI, SRI-UR or any unplanned coronary artery revascularization through to Week 12 and Week 24 are presented. |
| Secondary | Number of Participants With First Occurrence of the Composite of CV Death or Hospitalization for HF Through to Week 12 and Week 24 | Week 12, Week 24 | Number of participants with first occurrence of the composite of CV death or hospitalization for HF through to Week 12 and Week 24 are presented. |
| Secondary | Number of Participants With First Occurrence of the Composite of CV Death, MI or Stroke Through to Week 12 and Week 24 | Week 12, Week 24 | Number of participants with first occurrence of the composite of CV death, MI or stroke through to Week 12 and Week 24 are presented. |
| Secondary | Number of Participants With First Occurrence of the Expanded Composite of CV Death, MI, SRI-UR, Stroke or Hospitalization for HF Through to Week 12 and Week 24 | Week 12, Week 24 | Number of participants with first occurrence of the expanded composite of CV death, MI, SRI-UR, stroke or hospitalization for HF through to Week 12 and Week 24 are presented. |
| Secondary | Number of Participants With First Occurrence of the Composite of CHD Death, MI or SRI-UR Through to Week 12 and Week 24 | Week 12, Week 24 | Number of participants with first occurrence of the composite of CHD death, MI or SRI-UR through to Week 12 and Week 24 are presented. |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 registered outcomesOutcomes26
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Up to 12 weeks | Intent-To-Treat (ITT) Population. ITT population comprised of all randomized participants. | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of MACE Through Week 24 | Up to Week 24 | ITT Population. | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CV Death or MI up to Week 12 and Week 24 | Week 12 and Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CV Death, MI or Hospitalization for Heart Failure (HF) up to Week 12 and Week 24. | Week 12 and Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Expanded Composite of Arterial CV Events Defined as CV Death, MI, SRI-UR or Stroke Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of Coronary Events Defined as CHD Death, MI, SRI-UR or Any Unplanned Coronary Artery Revascularization Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CV Death or Hospitalization for HF Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CV Death, MI or Stroke Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Expanded Composite of CV Death, MI, SRI-UR, Stroke or Hospitalization for HF Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
| SECONDARY | Number of Participants With First Occurrence of the Composite of CHD Death, MI or SRI-UR Through to Week 12 and Week 24 | Week 12, Week 24 | ITT Population | Participants | NUMBER |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 outcomesResults by group110
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Placebo | First occurence of MACE | 123 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Losmapimod 7.5 mg BID | First occurence of MACE | 139 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Placebo | CV Death | 34 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Losmapimod 7.5 mg BID | CV Death | 31 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Placebo | MI | 74 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Losmapimod 7.5 mg BID | MI | 90 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Placebo | SRI-UR | 15 | Participants | |
| Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12 | Losmapimod 7.5 mg BID | SRI-UR | 18 | Participants | |
| Number of Participants With First Occurrence of MACE Through Week 24 | Placebo | First occurrence of MACE | 162 | Participants | |
| Number of Participants With First Occurrence of MACE Through Week 24 | Losmapimod 7.5 mg BID | First occurrence of MACE | 176 | Participants |
1 to 10 of 110Source ClinicalTrials.gov
See all 110 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 1,758 | |
| Overall Study | STARTED | Losmapimod 7.5 Mllligrms BID | 1,731 | |
| Overall Study | COMPLETED | Placebo | 1,753 | |
| Overall Study | COMPLETED | Losmapimod 7.5 Mllligrms BID | 1,723 | |
| Overall Study | NOT COMPLETED | Placebo | 5 | |
| Overall Study | NOT COMPLETED | Losmapimod 7.5 Mllligrms BID | 8 |
Source ClinicalTrials.gov
Adverse events808
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypertension | Vascular disorders | Placebo | 49 | 1,752 | |
| other | Hypertension | Vascular disorders | Losmapimod 7.5 mg BID | 33 | 1,724 | |
| other | Hypotension | Vascular disorders | Placebo | 29 | 1,752 | |
| other | Hypotension | Vascular disorders | Losmapimod 7.5 mg BID | 36 | 1,724 | |
| other | Troponin increased | Investigations | Placebo | 39 | 1,752 | |
| other | Troponin increased | Investigations | Losmapimod 7.5 mg BID | 23 | 1,724 | |
| other | Angina pectoris | Cardiac disorders | Placebo | 32 | 1,752 | |
| other | Angina pectoris | Cardiac disorders | Losmapimod 7.5 mg BID | 40 | 1,724 | |
| other | Atrial fibrillation | Cardiac disorders | Placebo | 65 | 1,752 | |
| other | Atrial fibrillation | Cardiac disorders | Losmapimod 7.5 mg BID | 72 | 1,724 |
1 to 10 of 808Source ClinicalTrials.gov
See all 808 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | 68 | 1,752 |
| Total, all-cause mortality | Losmapimod 7.5 mg BID | 57 | 1,724 |
| Total, other adverse events | Placebo | 370 | 1,752 |
| Total, other adverse events | Losmapimod 7.5 mg BID | 376 | 1,724 |
| Total, serious adverse events | Placebo | 323 | 1,752 |
| Total, serious adverse events | Losmapimod 7.5 mg BID | 363 | 1,724 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Losmapimod 7.5 mg BID vs Placebo: Number of Participants Re-hospitalized Within 30 Days of Discharge | Trial comparisons |
| Losmapimod 7.5 mg BID vs Placebo: deaths from any cause | Trial comparisons |
| Losmapimod 7.5 mg BID vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02145468
GET https://conductscience.org/api/trials/v1/NCT02145468/registered?page=2